What's The Difference Between Xeomin & Botox?
There's some really good information online about the difference between Xeomin & Botox.
We've put together a list of some of the best blog posts about this topic for you.
BOTOX vs DYSPORT vs XEOMIN – Differences Between Botulinum Toxin Type A Formulations.
By Dr Seiw
Since it was first used for cosmetic purposes almost 30 year ago, BOTOX has become synonymous with erasing wrinkles (and also become the butt of “frozen face” jokes). Botuinum Toxin (BoNT) type A is, in fact, a deadly toxin produced by the anaerobic bacteria Clostridium botulinum.
Everything You Need to Know About Xeomin, the Botox Alternative.
By MARIANNE MYCHASKIW
We've all heard the rumor circulating that, when injected enough times with Botox, your body has the ability to become immune to the toxin, rendering its muscle-freezing abilities useless. When your go-to treatment has started to lose its magic touch, rest assured that you have another option in Xeomin. Though we've only just heard about Xeomin, the treatment has been around in the dermatology and medi-spa worlds for years, and patients who have tried it claim it's so similar to Botox, they can't tell the difference in the end result.
I TRIED THE *OTHER* BOTOX AND THIS IS WHAT HAPPENED
By Katie Becker
The iconic Botox is not the only show in wrinkle-smoothing town. Most people don’t realize it, but there are two other almost identical injectables you can request from your dermatologist’s office called Xeomin and Dysport. The three are competitors in a class of drug called a neuromodulator. “Botox was the original one and has become the generic term, like Kleenex or Coke,” explains New York plastic surgeon David Shafer.
Want More Information?
Click this link to download a PDF from Xeomin.
Xeomin HCP abridged datasheet
is a Prescription Medicine. Please review full Product Information before
prescribing, available from New Zealand Medical & Scientific Ltd (NZMS) on 09 259 4062.
(Incobotulinumtoxin A, purified Botulinum toxin type A, free from complexing proteins,
powder for solution for injection). 50, 100 LD50 Units. Indications: In adults, for the treatment of
cervical dystonia; blepharospasm; post-stroke spasticity of the upper limb and upper facial lines
including forehead, periorbital (crow’s feet) and glabellar lines in adults. Contraindications:
Hypersensitivity to ingredients; generalised disorders of muscle activity (e.g. myasthenia gravis,
Lambert-Eaton Syndrome); Infection or inflammation at the proposed injection sites. Precautions:
bleeding disorders; local and distant spread of toxin effect; pre-existing neuromuscular disorders;
hypersensitivity reactions, antibody formation; lack of interchangeability between botulinum toxin
products; mild to severe dysphagia, aspiration and dyspnoea; muscle weakness (neck); swallowing,
speech or respiratory disorders; avoid injection through pen marks, into blood vessels, near levator
palpebrae superioris, inferior oblique and medial injections into the lower lid; ptosis; diplopia; reduced
blinking; contains albumin (human); pregnancy (Cat B3); lactation; children (not recommended);
driving/using machines; others, see full PI. Interactions with other medicines: Aminoglycoside
antibiotics; anticoagulants or those with similar effect; other agents interfering with neuromuscular
transmission, e.g., tubocurarine-type muscle relaxants. Adverse effects: Cervical Dystonia: neck
pain, muscular weakness, musculoskeletal pain and stiffness, dysphagia, nausea, headache, injection
site pain, Blepharospasm: dry eyes, eyelid ptosis, vision blurred, dry mouth, Poststroke spasticity:
muscle weakness Upper facial lines: headache, risk of eyelid, brow or lip ptosis; others, see full
PI. Dosage and Administration: For intramuscular injection, single use in one patient only. Unit
doses recommended for Xeomin are not interchangeable with those for other preparations of
botulinum toxin. Reconstitute with sodium chloride 9 mg/mL (0.9%) solution for injection (see full PI
for dilutions). The optimum dose and number of injection sites in the treated muscle(s) should be
individualised for each patient and determined by the treating doctor. Cervical dystonia: 0.1 to 0.5
mL/site; max 50 U/site; max 300 U/treatment session. Treatment intervals should be determined
based on the actual clinical need of the individual patient and generally no more frequent than every 6
weeks. Blepharospasm: 0.05-0.1 mL/ site; max 35 U/eye for pre-treated patients, if the previous dose
of botulinum toxin is not known; max 25 U/eye for treatment naïve patients; max 100 U per treatment
session. Treatment intervals should be determined based on the actual clinical need of the individual
patient and generally no more frequent than every 6 weeks. Post-stroke spasticity: max 400
U/treatment session; treatment intervals should be determined based on the actual clinical need of
the individual patient and generally no more frequent than every 12 weeks. Upper facial lines:
Glabellar -0.1 mL/site; max 30 U/treatment session; Periorbital – 0.1ml per site max 12 U per side;
Forehead – total dose 10 to 20 U ; treatment intervals should be determined based on the actual
clinical need of the individual patient and generally no more frequent than every 3 months; see full PI.
Medsafe-approved 18 December 2014. XEOMIN is a registered trademark of Merz Pharma GmbH &
Co. KGaA. Copyright ©2014. Prepared 18 February 2015. Xeomin is an unfunded medicine. For more
information please contact the New Zealand Distributor: New Zealand Medical and Scientific Ltd, 2a
Fisher Crescent, Mt Wellington, Auckland, Phone 09 259 4062. TAPS NA9800.
Xeomin Abridged information for DTCA
Xeomin® is a Prescription Medicine containing 50, 100 LD50 Units of clostridium botulinum Type A toxin
complex for injection. It is used for the treatment of frown lines on the forehead, lateral periorbital lines
and horizontal forehead lines in adults. It should be administered only by trained medical professionals.
Talk to your specialist about the benefits/risks of this procedure in appearance medicine. Xeomin treatment
lasts about four months and further courses of treatment may be necessary. Cautions: Generalised
disorders of muscle activity; Infection or inflammation at the proposed injection sites, pregnancy and
lactation. Possible side effects: headache, pain, swelling or infection at injection site, local muscle
weakness including drooping eye lids, lack of feeling & nausea. You will need to pay for this medicine.
Discuss with your specialist if Xeomin is right for you. For more information or for a copy of CMI please
contact the NZ distributor: NZMS Ltd: 2a Fisher Crescent, Mt Wellington, Auckland, Ph 09 259 4062.TAPS